1245830-90-3

Upstream product

• 20439-47-8 (1R,2R)-1,2-diaminocyclohexane 
• 5750-76-5 2,4,5-trichloropyrimidine 

Downstream Products

• 1022971-87-4 N-[(1R,2R)-2-(2,5-dichloropyrimidin-4-ylamino)cyclohexyl]acetamide 
• 1022973-35-8 N-[(1R,2R)-2-(2,5-dichloropyrimidin-4-ylamino)cyclohexyl]-2,2,2-trifluoroacetamide 
• 1022950-54-4 N-[(1R,2R)-2-(2,5-dichloro-pyrimidin-4-ylamino)cyclohexyl]methanesulfonamide 
• 1022973-42-7 N-((1R,2R)-2-{5-chloro-2-[3-(2-methoxyethyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ylamino]pyrimidin-4-ylamino}cyclohexyl)-2,2,2-trifluoroacetamide 
• 1022973-33-6 N-{(1R,2R)-2-[5-chloro-2-(3-ethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ylamino)pyrimidin-4-ylamino]cyclohexyl}-2,2,2-trifluoroacetamide 
• 1022956-07-5 N-((1R,2R)-2-{5-chloro-2-[3-(2-methoxyethyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ylamino]-pyrimidin-4-ylamino}cyclohexyl)methanesulfonamide 
• 1022973-19-8 N-{(1R,2R)-2-[5-chloro-2-(3-ethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ylamino)pyrimidin-4-ylamino]cyclohexyl}methanesulfonamide 
• 1022955-46-9 C₁₃H₂₀Cl₂N₄O₂S 
• 1022955-38-9 N-[(1R,2R)-2-(2,5-dichloropyrimidin-4-ylamino)cyclohexyl]-N-methyl-methanesulfonamide 
• 1259274-55-9 C₂₂H₃₁ClN₆ 
• 1022955-52-7 N-((1R,2R)-2-{5-chloro-2-[8-methoxy-3-(2-methoxyethyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ylamino]pyrimidin-4-ylamino}cyclohexyl)-N-ethylmethanesulfonamide 
• 1022955-49-2 N-((1R,2R)-2-{5-chloro-2-[8-methoxy-3-(2-methoxyethyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ylamino]pyrimidin-4-ylamino}cyclohexyl)-N-methyl-methanesulfonamide 
• 1022960-28-6 N-((1R,2R)-2-{5-chloro-2-[8-methoxy-3-(2-methoxyethyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ylamino]pyrimidin-4-ylamino}cyclohexyl)methanesulfonamide 
• 1022973-31-4 N-{(1R,2R)-2-[5-chloro-2-(3-ethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ylamino)pyrimidin-4-ylamino]cyclohexyl}acetamide 

Relevant academic research and scientific papers

Methanesulfonamido-cyclohexylamine derivatives of 2,4-diaminopyrimidine as potent ALK inhibitors

The incorporation of R,R-1,2-diaminocyclohexane at C4 in a series of 2,4-diaminopyrimidines led to a number of ALK inhibitors in which optimized activity was achieved by conversion of the 2-amino group into a methanesulfonamide. Tumor growth inhibition wa

SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF CANCER

The present invention encompasses compounds of general formula (1) wherein B, R1 to R5, Rx, m and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use in such treatment.